Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237801 | 1.00 | DRD2 (0.43) | DRD2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL8515074 | 0.89 | DRD2 (0.42) | DRD2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL8531940 | 0.89 | DRD2 (0.42) | DRD2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL8531446 | 0.89 | DRD2 (0.42) | DRD2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL8537824 | 0.89 | DRD2 (0.42) | DRD2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL9932272 | 0.77 | DRD4 (0.41) | DRD2SIGMAR1DRD4ACHESMN1; SMN2 | |
| SCHEMBL10237792 | 0.76 | SLC18A3 (0.41) | SIGMAR1DRD4ACHEMCHR1HRH3 | |
| SCHEMBL8535101 | 0.67 | SLC18A3 (0.40) | DRD2SIGMAR1DRD4ACHEMCHR1 | |
| SCHEMBL13726456 | 0.66 | SIGMAR1 (0.57) | SIGMAR1DRD4ACHEHRH3SMN1; SMN2 | |
| SCHEMBL28728795 | 0.66 | SIGMAR1 (0.56) | SIGMAR1DRD4ACHESMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | DRD2 4374/4885SIGMAR1 4067/4885HTR2A 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.